Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | DDO | Q99489 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.36 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9054601 | 0.84 | KDM3B (0.39) | KMT2ACYP2C9MAPTHTTCYP1A2 | |
| SCHEMBL5983288 | 0.82 | KMT2A (0.44) | KMT2ACYP2C9MAPTHTTCYP1A2 | |
| SCHEMBL10823650 | 0.81 | KMT2A (0.53) | KMT2ACYP2C9MAPTHTTCYP1A2 | |
| SCHEMBL31282172 | 0.78 | KMT2A (0.49) | KMT2ACYP2C9MAPTHTTCYP1A2 | |
| SCHEMBL10823643 | 0.77 | HTT (0.56) | KMT2ACYP2C9MAPTHTTCYP1A2 | |
| SCHEMBL11239615 | 0.76 | CYP2C19 (0.69) | KMT2ACYP2C9MAPTHTTCYP1A2 | |
| SCHEMBL17278321 | 0.75 | LMNA (0.50) | KMT2ACYP1A2SMN1; SMN2HPGDKDM4E | |
| SCHEMBL6572744 | 0.75 | GRIA1 (0.49) | HPGDMAPK1GRIA1GRIA2GRIA4 | |
| SCHEMBL11238675 | 0.74 | CYP2C19 (0.79) | KMT2ACYP2C9MAPTHTTCYP1A2 | |
| SCHEMBL8672229 | 0.72 | KMT2A (0.45) | KMT2ACYP2C9MAPTHTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 491 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146073-A1 | T CELL RECEPTORS TARGETING MUTATED CDKN2A | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2026-05-28 | — | — | US | disclosed |
| US-12638452-B2 | Nanopore assemblies and uses thereof | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-05-26 | — | — | US | disclosed |
| US-20250332186-A1 | Methods and Compositions Relating to p62/SQSTM1 for the Treatment and Prevention of Inflammation-Associated Diseases | CURELAB ONCOLOGY INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250263462-A1 | ANTI-MUTATED KRAS T CELL RECEPTORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250018040-A1 | ANTI-MESOTHELIN POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2025-01-16 | — | — | US | disclosed |
| CN-118949941-A | Nanopore assembly and uses thereof | 牛津纳米孔科技公开有限公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240299510-A1 | ANTIBODY-GUIDED PCSK9-MIMICKING IMMUNOGENS LACKING 9-RESIDUE SEQUENCE OVERLAP WITH HUMAN PROTEINS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240265999-A1 | METHODS AND SYSTEMS FOR METAGENOMICS ANALYSIS | IDBYDNA INC. | 2024-08-08 | — | — | US | disclosed |
| US-12054742-B2 | Compositions and methods to derive mesodermal lineage cells and mixed tissue organoids from embryonic stem cells | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240229051-A9 | CHLOROPLAST CYTOSINE BASE EDITORS AND MITOCHONDRIA CYTOSINE BASE EDITORS IN PLANTS | NATIONAL SCIENCE FOUNDATION | 2024-07-11 | — | — | US | disclosed |
| WO-2001042305-A1 | INTERLEUKIN-1 RECEPTOR ANTAGONIST-LIKE MOLECULES AND USES THEREOF | AMGEN, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| WO-2001042304-A1 | INTERLEUKIN-1 RECEPTOR ANTAGONIST-RELATED MOLECULES AND USES THEREOF | AMGEN, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| WO-2001042465-A2 | CHORDIN-LIKE MOLECULES AND USES THEREOF | AMGEN, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| WO-2001011050-A1 | Fhm, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY | AMGEN INC. (US) | 2001-02-15 | — | — | WO | disclosed |
| WO-2001010908-A1 | NTR3, A MEMBER OF THE TNF-RECEPTOR SUPERGENE FAMILY | AMGEN INC. (US) | 2001-02-15 | — | — | WO | disclosed |
| WO-2001007074-A1 | VGF SELECTIVE BINDING AGENTS AND METHODS OF TREATING VGF-RELATED DISORDERS | AMGEN, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001007477-A1 | VGF POLYPEPTIDES AND METHODS OF TREATING VGF-RELATED DISORDERS | AMGEN, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-0476071-A4 | EXONUCLEASE-RESISTANT OLIGONUCLEOTIDES AND METHODS FOR PREPARING THE SAME | — | 1992-11-04 | — | — | EP | disclosed |
| EP-0476071-A1 | EXONUCLEASE-RESISTANT OLIGONUCLEOTIDES AND METHODS FOR PREPARING THE SAME | GILEAD SCIENCES, INC. (US) | 1992-03-25 | — | — | EP | disclosed |
| WO-1990015065-A1 | EXONUCLEASE-RESISTANT OLIGONUCLEOTIDES AND METHODS FOR PREPARING THE SAME | GILEAD SCIENCES, INC. (US) | 1990-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146073-A1 | T CELL RECEPTORS TARGETING MUTATED CDKN2A | TP53, CD74, HLA-C | KMT2A 1370/4885CYP2C9 3468/4885MAPT 4121/4885 |
| US-12638452-B2 | Nanopore assemblies and uses thereof | FAM83A, SCNN1G, SCN3A | KMT2A 1925/4885CYP2C9 3699/4885MAPT 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.